Cargando…
Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios alone or combined with prostate-specific antigen for the diagnosis of prostate cancer and clinically significant prostate cancer
OBJECTIVE: We evaluated whether the blood parameters before prostate biopsy can diagnose prostate cancer (PCa) and clinically significant PCa (Gleason score [GS] ≥7) in our hospital. METHODS: This study included patients with increased prostate-specific antigen (PSA) up to 20 ng/mL. The associations...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Second Military Medical University
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10023529/ https://www.ncbi.nlm.nih.gov/pubmed/36942115 http://dx.doi.org/10.1016/j.ajur.2022.02.007 |
_version_ | 1784908902622560256 |
---|---|
author | Nepal, Sat Prasad Nakasato, Takehiko Fukagai, Takashi Ogawa, Yoshio Nakagami, Yoshihiro Shichijo, Takeshi Morita, Jun Maeda, Yoshiko Oshinomi, Kazuhiko Unoki, Tsutomu Noguchi, Tetsuo Inoue, Tatsuki Kato, Ryosuke Amano, Satoshi Mizunuma, Moyuru Kurokawa, Masahiro Tsunokawa, Yoshiki Yasuda, Sou |
author_facet | Nepal, Sat Prasad Nakasato, Takehiko Fukagai, Takashi Ogawa, Yoshio Nakagami, Yoshihiro Shichijo, Takeshi Morita, Jun Maeda, Yoshiko Oshinomi, Kazuhiko Unoki, Tsutomu Noguchi, Tetsuo Inoue, Tatsuki Kato, Ryosuke Amano, Satoshi Mizunuma, Moyuru Kurokawa, Masahiro Tsunokawa, Yoshiki Yasuda, Sou |
author_sort | Nepal, Sat Prasad |
collection | PubMed |
description | OBJECTIVE: We evaluated whether the blood parameters before prostate biopsy can diagnose prostate cancer (PCa) and clinically significant PCa (Gleason score [GS] ≥7) in our hospital. METHODS: This study included patients with increased prostate-specific antigen (PSA) up to 20 ng/mL. The associations of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) alone or with PSA with PCa and clinically significant PCa were analyzed. RESULTS: We included 365 patients, of whom 52.9% (193) had PCa including 66.8% (129) with GS of ≥7. PSA density (PSAD) and PSA had better the area under the curve (AUC) of 0.722 and 0.585, respectively with p=0.001 for detecting PCa compared with other blood parameters. PSA combined with PLR (PsPLR) and PSA with NLR (PsNLR) had better AUC of 0.608 and 0.610, respectively with p<0.05, for diagnosing GS≥7 population, compared with PSA, free/total PSA, NLR, PLR, and PsNPLR (PSA combined with NLR and PLR). NLR and PLR did not predict PCa on multivariate analysis. For GS≥7 cancer detection, in the multivariate analysis, separate models with PSA and NLR (Model 1: PsNLR+baseline parameters) or PSA and PLR (Moder 2: PsPLR+baseline parameters) were made. Baseline parameters comprised age, digital rectal exam-positive lesions, PSA density, free/total PSA, and magnetic resonance imaging. Model 2 containing PsPLR was statistically significant (odds ratio: 2.862, 95% confidence interval: 1.174–6.975, p=0.021) in finding aggressive PCa. The predictive accuracy of Model 2 was increased (AUC: 0.734, p<0.001) than that when only baseline parameters were used (AUC: 0.693, p<0.001). CONCLUSION: NLR or PLR, either alone or combined with PSA, did not detect PCa. However, the combined use of PSA with PLR could find the differences between clinically significant and insignificant PCa in our retrospective study limited by the small number of samples. |
format | Online Article Text |
id | pubmed-10023529 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Second Military Medical University |
record_format | MEDLINE/PubMed |
spelling | pubmed-100235292023-03-19 Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios alone or combined with prostate-specific antigen for the diagnosis of prostate cancer and clinically significant prostate cancer Nepal, Sat Prasad Nakasato, Takehiko Fukagai, Takashi Ogawa, Yoshio Nakagami, Yoshihiro Shichijo, Takeshi Morita, Jun Maeda, Yoshiko Oshinomi, Kazuhiko Unoki, Tsutomu Noguchi, Tetsuo Inoue, Tatsuki Kato, Ryosuke Amano, Satoshi Mizunuma, Moyuru Kurokawa, Masahiro Tsunokawa, Yoshiki Yasuda, Sou Asian J Urol Original Article OBJECTIVE: We evaluated whether the blood parameters before prostate biopsy can diagnose prostate cancer (PCa) and clinically significant PCa (Gleason score [GS] ≥7) in our hospital. METHODS: This study included patients with increased prostate-specific antigen (PSA) up to 20 ng/mL. The associations of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) alone or with PSA with PCa and clinically significant PCa were analyzed. RESULTS: We included 365 patients, of whom 52.9% (193) had PCa including 66.8% (129) with GS of ≥7. PSA density (PSAD) and PSA had better the area under the curve (AUC) of 0.722 and 0.585, respectively with p=0.001 for detecting PCa compared with other blood parameters. PSA combined with PLR (PsPLR) and PSA with NLR (PsNLR) had better AUC of 0.608 and 0.610, respectively with p<0.05, for diagnosing GS≥7 population, compared with PSA, free/total PSA, NLR, PLR, and PsNPLR (PSA combined with NLR and PLR). NLR and PLR did not predict PCa on multivariate analysis. For GS≥7 cancer detection, in the multivariate analysis, separate models with PSA and NLR (Model 1: PsNLR+baseline parameters) or PSA and PLR (Moder 2: PsPLR+baseline parameters) were made. Baseline parameters comprised age, digital rectal exam-positive lesions, PSA density, free/total PSA, and magnetic resonance imaging. Model 2 containing PsPLR was statistically significant (odds ratio: 2.862, 95% confidence interval: 1.174–6.975, p=0.021) in finding aggressive PCa. The predictive accuracy of Model 2 was increased (AUC: 0.734, p<0.001) than that when only baseline parameters were used (AUC: 0.693, p<0.001). CONCLUSION: NLR or PLR, either alone or combined with PSA, did not detect PCa. However, the combined use of PSA with PLR could find the differences between clinically significant and insignificant PCa in our retrospective study limited by the small number of samples. Second Military Medical University 2023-04 2022-03-05 /pmc/articles/PMC10023529/ /pubmed/36942115 http://dx.doi.org/10.1016/j.ajur.2022.02.007 Text en © 2022 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Nepal, Sat Prasad Nakasato, Takehiko Fukagai, Takashi Ogawa, Yoshio Nakagami, Yoshihiro Shichijo, Takeshi Morita, Jun Maeda, Yoshiko Oshinomi, Kazuhiko Unoki, Tsutomu Noguchi, Tetsuo Inoue, Tatsuki Kato, Ryosuke Amano, Satoshi Mizunuma, Moyuru Kurokawa, Masahiro Tsunokawa, Yoshiki Yasuda, Sou Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios alone or combined with prostate-specific antigen for the diagnosis of prostate cancer and clinically significant prostate cancer |
title | Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios alone or combined with prostate-specific antigen for the diagnosis of prostate cancer and clinically significant prostate cancer |
title_full | Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios alone or combined with prostate-specific antigen for the diagnosis of prostate cancer and clinically significant prostate cancer |
title_fullStr | Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios alone or combined with prostate-specific antigen for the diagnosis of prostate cancer and clinically significant prostate cancer |
title_full_unstemmed | Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios alone or combined with prostate-specific antigen for the diagnosis of prostate cancer and clinically significant prostate cancer |
title_short | Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios alone or combined with prostate-specific antigen for the diagnosis of prostate cancer and clinically significant prostate cancer |
title_sort | neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios alone or combined with prostate-specific antigen for the diagnosis of prostate cancer and clinically significant prostate cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10023529/ https://www.ncbi.nlm.nih.gov/pubmed/36942115 http://dx.doi.org/10.1016/j.ajur.2022.02.007 |
work_keys_str_mv | AT nepalsatprasad neutrophiltolymphocyteandplatelettolymphocyteratiosaloneorcombinedwithprostatespecificantigenforthediagnosisofprostatecancerandclinicallysignificantprostatecancer AT nakasatotakehiko neutrophiltolymphocyteandplatelettolymphocyteratiosaloneorcombinedwithprostatespecificantigenforthediagnosisofprostatecancerandclinicallysignificantprostatecancer AT fukagaitakashi neutrophiltolymphocyteandplatelettolymphocyteratiosaloneorcombinedwithprostatespecificantigenforthediagnosisofprostatecancerandclinicallysignificantprostatecancer AT ogawayoshio neutrophiltolymphocyteandplatelettolymphocyteratiosaloneorcombinedwithprostatespecificantigenforthediagnosisofprostatecancerandclinicallysignificantprostatecancer AT nakagamiyoshihiro neutrophiltolymphocyteandplatelettolymphocyteratiosaloneorcombinedwithprostatespecificantigenforthediagnosisofprostatecancerandclinicallysignificantprostatecancer AT shichijotakeshi neutrophiltolymphocyteandplatelettolymphocyteratiosaloneorcombinedwithprostatespecificantigenforthediagnosisofprostatecancerandclinicallysignificantprostatecancer AT moritajun neutrophiltolymphocyteandplatelettolymphocyteratiosaloneorcombinedwithprostatespecificantigenforthediagnosisofprostatecancerandclinicallysignificantprostatecancer AT maedayoshiko neutrophiltolymphocyteandplatelettolymphocyteratiosaloneorcombinedwithprostatespecificantigenforthediagnosisofprostatecancerandclinicallysignificantprostatecancer AT oshinomikazuhiko neutrophiltolymphocyteandplatelettolymphocyteratiosaloneorcombinedwithprostatespecificantigenforthediagnosisofprostatecancerandclinicallysignificantprostatecancer AT unokitsutomu neutrophiltolymphocyteandplatelettolymphocyteratiosaloneorcombinedwithprostatespecificantigenforthediagnosisofprostatecancerandclinicallysignificantprostatecancer AT noguchitetsuo neutrophiltolymphocyteandplatelettolymphocyteratiosaloneorcombinedwithprostatespecificantigenforthediagnosisofprostatecancerandclinicallysignificantprostatecancer AT inouetatsuki neutrophiltolymphocyteandplatelettolymphocyteratiosaloneorcombinedwithprostatespecificantigenforthediagnosisofprostatecancerandclinicallysignificantprostatecancer AT katoryosuke neutrophiltolymphocyteandplatelettolymphocyteratiosaloneorcombinedwithprostatespecificantigenforthediagnosisofprostatecancerandclinicallysignificantprostatecancer AT amanosatoshi neutrophiltolymphocyteandplatelettolymphocyteratiosaloneorcombinedwithprostatespecificantigenforthediagnosisofprostatecancerandclinicallysignificantprostatecancer AT mizunumamoyuru neutrophiltolymphocyteandplatelettolymphocyteratiosaloneorcombinedwithprostatespecificantigenforthediagnosisofprostatecancerandclinicallysignificantprostatecancer AT kurokawamasahiro neutrophiltolymphocyteandplatelettolymphocyteratiosaloneorcombinedwithprostatespecificantigenforthediagnosisofprostatecancerandclinicallysignificantprostatecancer AT tsunokawayoshiki neutrophiltolymphocyteandplatelettolymphocyteratiosaloneorcombinedwithprostatespecificantigenforthediagnosisofprostatecancerandclinicallysignificantprostatecancer AT yasudasou neutrophiltolymphocyteandplatelettolymphocyteratiosaloneorcombinedwithprostatespecificantigenforthediagnosisofprostatecancerandclinicallysignificantprostatecancer |